Cargando…
Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
Respiratory syncytial virus (RSV) causes seasonal respiratory infection, with hospitalization rates of up to 50% in high-risk infants. Palivizumab provides safe and effective, yet costly, immunoprophylaxis. The American Academy of Pediatrics (AAP) recommends palivizumab only for high-risk infants an...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139984/ https://www.ncbi.nlm.nih.gov/pubmed/34021214 http://dx.doi.org/10.1038/s41598-021-90107-8 |